INTRODUCTION
Although rates of opioid abuse found in Turkey are lower than North America and Europe 1 , opioid abuse is an increasing public health problem in Turkey, both due to the use of heroin and to an increasing number of individuals developing dependence on prescription opioids 2, 3 . Illicit use of opioids has been associated with considerable societal costs, including increased rates of emergency department visits, drug overdoses, criminal activity, lost work days and general medical and psychiatric consequences [4] [5] [6] [7] . Similar to the trend in North America and Europe 2 , treatment admissions for opioid abuse and d e p e n d e n c e i n T u r k e y h a v e i n c r e a s e d dramatically in recent years.
Buprenorphine is a partial opioid agonist of the mu receptor, with antagonistic properties at the kappa receptor 8 . To prevent buprenorphine abuse, buprenorphine is typically packaged with naloxone (buprenorphine/naloxone -BN, Suboxone ® ), which yields no effect when administered sublingually but exerts antagonist properties when injected 8, 9 . Opioid maintanence treatment (OMT) for opioid dependence such as BN, is effective in reducing mortality, HIV transmission, crime, and other drug use 10, 11 . BN has also been shown to be a safe and effective treatment of opioid dependence in nonspecialized, outpatient, office-based settings [12] [13] [14] . Abstinence-oriented symptomatic treatment was the most commonly offered treatment option in Turkey until the end of 2009. Starting from beginning of 2010, the BN combination was approved for opioid dependence treatment as a detoxification or a maintenance treatment by the Turkish Ministry of Health 15 which served as an opportunity to increase the number of patients with opioid dependence receiving treatment. The number of prescriptions for BN has increased steadily since its approval and BN has been associated with bringing new users into treatment. Prescribing BN is restricted to hospitals that have a state-approved specialized clinic for treatment of substance dependency. Consistent with this, physician adoption has been primarily among addiction specialists who make up all the prescribers in Turkey. After approval of treatment by authorized bodies, the Alcohol and Drug Research, Treatment and Training Center (AMATEM) in Istanbul started providing BN OMT to the hospitalized patients only. Thus due to limited resources, there was a long waiting list to get into this maintenance program. At the beginning of 2011 AMATEM wrote a guideline 16 and started implementation of BN maintenance treatment on an outpatient basis.
The central problem in the treatment of heroin dependency is high rates of relapse to drug use after periods of forced or self-imposed abstinence 17 . Retention in OMT has been associated with improved outcomes in adults [18] [19] [20] , and discontinuation of therapy has been associated with relapse 21 , overdose death 22 , and worse HIV treatment outcomes 23 . Retention rates for BN maintenance treatment at 6 months ranged from 35% to 59% 12, 14, 24 , and a 38% retention was reported in one study that followed patients for 2 years 25 . In another study the overall retention rate was recorded as 56.9% (64.7% of their months were opioid-negative) for 1 year, with about half of the dropouts occurring in the first month 26 . Pinto et al. 27 reported that among 134 opioid dependent patients, 61.2% were retained in treatment at 3 months and 42.5% were retained in treatment at 6 months. Finally in a recent study Schwarz et al. 28 reported that over one third (37.2%) of the sample discontinued BN maintenance treatment within the first month following induction, while 25% of the sample stayed for at least 43 months in treatment 28 . There are few studies of OMT outcomes that consider what factors might be associated with treatment dropout or what might be done to i m p r ov e d r o p o u t r a t e s. P r e -t r e a t m e n t characteristics, most consistently associated with poorer outcome among heroin dependent patients in BN maintenance treatment, include; male gender, lack of employment, younger age at onset of opioid use, more continuous and longer opioid use, use of heroin rather than other opioids as the primary drug, higher levels of psychiatric symptoms, lower levels of general functioning, poorer psychosocial functioning and more severe legal problems 14, [29] [30] [31] [32] [33] [34] [35] [36] . However, depression was associated with treatment retention in two studies 34, 37 . During treatment, predictors of negative outcomes in heroin dependents included lower doses, greater severity of withdrawal, side effects, more positive urine tests for opioids and other drugs, opioid positive drug screens at week 1, and fewer addiction counseling sessions 10, 14, 35, 38 . This is the first report of early treatment characteristics associated with treatment outcomes among Turkish heroin dependents in BN maintenance treatment, which is the only agent that is used for maintenance treatment in Turkey. Thus, the aim of this study was to evaluate the outcomes of patients, who were prescribed sublingual BN as a maintenance treatment during a 6-month follow-up and to identify early treatment characteristics associated with outcomes in heroin dependent patients.
METHODS

Settings and Sample
The study was conducted in the Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research Treatment and Training Center (AMATEM) in Istanbul. The patient's written informed consent was obtained after the study protocol was thoroughly explained.
The decision with respect to treatment type, i.e. outpatient or inpatient, was determined by the written AMATEM guideline 16 . According to this guideline, patients who have been diagnosed as being opioid dependent for at least two years, who abuse depressants such as alcohol or benzodiazepine, who use polysubstances and those who have dropped-out of outpatient OMT twice in a year are given BN maintenance treatment as an inpatient.
The induction and stabilization phase ends after one to two weeks. Baseline interviews with the patients were done before induction of the BN. Both outpatients and inpatients (after being discharged from the hospital) were advised to participate to the Outpatient Treatment Program (OTP) once a week for at least one year, whereas they were obligated to come to the outpatient treatment unit every month to have BN prescribed. The prescribed BN doses ranged from 2 to 24 mg per day, with most patients receiving 8 to 12 mg per day.
The primary outcome measure was abstinence from heroine and other drugs, as documented by urine toxicology and self-reports, at consecutive 6-month intervals after induction of maintenance treatment. Thus, the proportion of patients remaining in maintenance treatment (the percentage of patients who were given prescriptions for BN maintenance treatment, who did not use heroine or other drugs, who did not miss their medication for 7 days, or did not miss psychiatric evaluations each month) was used. Urinalyses were conducted with the use of a s e m i q u a n t i t a t i v e h o m o g e n e o u s e n z y m e immunoassay for buprenorphine, opioids, cocaine, marijuana, amphetamine, ecstacy, benzodiazepines and alcohol.
Evaluation
Baseline evaluation was conducted between March 2012 and July 2012. Four hundred and twenty consecutive heroin-dependent patients were considered for participation in the study. All participants met the DSM-IV diagnostic criteria for heroin dependence. The exclusion criteria were illiteracy, mental retardation or cognitive impairment and comorbid psychotic disorder. Thus, six patients were excluded due to illiteracy and four patients due to cognitive deficits. Although none of the patients refused to participate in the study, 18 patients were excluded as they left some parts of the scales unfilled, did not give the forms back or left the treatment program prematurely; i.e. before completing the forms. Therefore, a total of 392 heroin-dependent inpatients participated in the study. Onset of the follow-up was defined as initiation of BN for outpatientsand being discharged from the hospital for inpatients.
Measures
All patients were assessed by using a semistructured socio-demographic form. The diagnosis of heroin dependence in each participating patient was based on the clinical examination, a screening interview based on the Structured Clinical Interview for DSM-IV (SCID-I) 39 Turkish version 40 , conducted by a trained interviewer (CE) at the baseline.
Bakirkoy Opioid Witdrawal Scale (BOWS):
The Bakirkoy Opioid Withdrawal Scale (BOWS) is a clinician rated scale that has been used since 1995 in Bakirkoy AMATEM. The BOWS includes 13 symptoms of opioid withdrawal which are simply rated as present or absent. Each "present" answer scores as 1, thus the total score of the scale is 13, which shows the most severe withdrawal. Two components on the BOWS reached the criterion of an Eigenvalue greater than one (3.98 and 1.40) and the variance accounted for by these components were 30.61% and 10.76% respectively. The first factor consisted of general withdrawal symptoms (GWS -dysphoric mood, muscle aches, lacrimation, rhinorrhea, dilated pupils, piloerection, sweating, excessive yawning, fever) and the second factor consisted of gastrointestinal symptoms (GIS -nausea, vomiting, stomachache, diarrhea). All item-component loadings were in the "good" to "excellent" range. Internal consistency reliability for the BOWS, examined by Cronbach's alpha, was also high (coefficient α=0.81) 41 .
Substance Craving Scale (SCS):
Craving for substance use was evaluated using SCS. SCS is a version of the Penn Alcohol Craving Scale (PACS), which is a 5-item questionnaire developed to evaluate the desire for alcohol use during the previous week (frequency, severity, duration, resistance, and general craving) 42, 43 . Each item is scored between 0 and 6, and the maximum craving score is 30. SCS is the version of the PACS for evaluating craving in substance use disorders. Cronbach's alpha value for the SCS is 0.84. The overall item-total correlation values corrected for each item varies between 0.75 and 0.82 44 .
The Drug Use Disorders Identification Test (DUDIT):
The DUDIT is frequently used in the drug abuse field and has demonstrated sound psychometric properties 45 . The DUDIT is an 11-item self-report questionnaire that was developed as an analogous instrument to the Alcohol Use Disorders Identification Test (AUDIT) 46 to screen individuals for drug problems. In their initial investigation of the psychometric properties of the DUDIT, Berman et al. 47 used both general and clinical population samples. The first nine questions are scored on 5-point scales ranging from 0 to 4, and last two are scored on 3-point scales with values of 0, 2, and 4. Thus, total scores range from 0 to 44, with higher scores suggestive of a more severe drug problem. The Turkish version of the DUDIT has a Cronbach's alpha of 0.93 and a single component accounted for 58.65% of total variance. Additionally, the DUDIT showed good discriminant validity as it significantly differentiated patients with drug use disorder from alcohol dependents 48 .
The Drug Abuse Screening Test (DAST-10):
The DAST-10 is frequently used in the field of drug abuse, and has demonstrated sound psychometric p r o p e r t i e s 4 9 . T h e DA S T a s s e s s e s d r u g consequences and problem severity in the past year 50 . The original 28-item DAST, modeled after the Michigan Alcoholism Screening Test 51 , has a unidimensional construct when factor analyzed 50 . All versions of the DAST (28-, 20-and 10-item) have been found to have moderate to high levels of validity, sensitivity, and specificity 49 . Since the 10-item version of the DAST (DAST-10) has comparable sensitivity and specificity to its 28-and 20-item counterparts 49 , the former was used in the present study. For the DAST-10, scores range from 0 to 10. The Turkish version has a Cronbach's alpha of 0.90 and a single component accounted for 59.35% of total variance. Additionally, the DAST-10 showed good discriminant validity as it significantly differentiated patients with drug use disorder from alcohol dependents 52 .
The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES):
The SOCRATES is a 19-item self-report questionnaire developed by Miller and Tonigan 53 for evaluating the level of readiness for change and motivation to change in individuals with a substance use disorder. Factor analysis of the original scale indicated that the form measures three domains: recognition, ambivalence, and taking steps. The factorial structure of the 16-item Turkish version was reported to be compatible with the original version of the scale 54 . When its 16-item Turkish version (Cronbach's alpha=0.85), which was reported to be valid and reliable in Turkish alcohol-dependent individuals, was administered to drug-dependent individuals its Cronbach's alpha value was 0.84 for the total scale 55 .
Statistical Methods
The statistical package SPSS 11.5 for Windows was used for all the analyses. Categorical variables were compared by means of chi-square statistics. We used the Student t test to compare the groups on continuous variables, since these variables were normally distributed. In addition, a One-way Anova was used to compare three groups, namely relapsed, maintenance and dropout, on continuous variables. Logistic Regression models (Forward) were performed to evaluate variables that predict negative outcome (relapse/drop-out) in first and sixth months. In both of these models, the independent variables were having a firstdegree relative with substance abuse, history of suicide attempts, being under probation, severity of withdrawal and craving. Moreover, Logistic Regression models were conducted where the independent variables were items of the SCS. In the second step of both of these models, treatment type (inpatient-outpatient) was added as an independent variable into the analyses. Since this study was cross-sectional, results of these regression analyses should be interpreted with caution. The term 'predictors' in the present study is used as a more general term to classify all independent variables in regression analyses, rather than describing causal relationships.
RESULTS
Among 392 heroin dependent patients, 287 (73.21%) were considered to be RDG, whereas 105 (26.79%) were considered to be those who were retained in BN maintenance (BNM) treatment. The rates and means of some sociodemographic and clinical variables for the total sample and the comparison between the RD and BNM groups are shown in Table 1 . The rates of having a first-degree relative with substance abuse, being under probation and history of suicide attempts were higher in the relapsed group. Other than these, the sociodemographic variables did not differ between groups (Table 1) .
Mean scores of the BOWS and SCS were higher in the RDG than the maintenance group, whereas the DUDIT, DAST-10, SOCRATES scores and the mean dose of BN did not differ between the groups (Table 2) .
We also compared variables according to four groups, namely relapsed to heroin use relapsed to other substance use, maintenance and dropout groups. Table 3 compares inpatient and outpatient groups according to the status of retention in the treatment. The rate of not attending the outpatient treatment unit at the end of the first month was 27.3% (24.5% for inpatients, 28.3% for outpatients). At the end of the 6th month, 105 patients (26.79%) had been retained in the treatment. This rate was 22.4% for outpatients, whereas it was 38.7% for inpatients (Table 3) . The rates of retention in the treatment (those who received prescriptions for BN maintenance treatment) were higher among the inpatient group than the outpatient group in both the first (Odds Ratio=2.74) and sixth months (Odds Ratio=1.92) ( Table 3 ).
In the first month the mean craving score was higher in the group relapsed to heroin use (n=60, 23 At the end of the 6 th month, severity of craving predicted a patient falling into the RDG, together with a history of suicide attempts and being under probation. When type of treatment was included in the regression analyses as an independent variable, outpatient treatment predicted a negative outcome, together with history of suicide attempts and being under probation. Among the 5 items of the craving scale, item 2 (which is "severity of craving"), predicted a negative outcome even when type of treatment was entered into the analysis as an independent variable (Table 4) .
DISCUSSION
The present study examined patients' pretreatment characteristics associated with the outcome of 6-month BN maintenance treatment plus medical management, with or without adjunctive drug counseling, in a large sample of heroin dependent patients. In bivariate analyses, patients that relapsed to substance use or those considered as dropouts from treatment had (1) higher rates of substance abuse among first-degree relatives, (2) a higher likelihood of being under probation, (3) a history of suicide attempts, (4) higher severity of withdrawal, and (5) craving. In regression analysis, craving was associated with a negative outcome (relapse/dropout) together with history of suicide attempts and being under probation. When type of treatment (inpatient/ outpatient) was also taken as an independent variable, outpatient treatment predicted a negative outcome instead of craving, together with history of suicide attempts and being under probation. This suggests that although the severity of craving is an important risk factor dropping out of treatment, two weeks of supervised treatment with additional educational programs in the stabilization phase may be helpful to these patients to continue maintenance treatment. Finally, history of a suicide attempts and being under probation are two risk factors for a negative outcome, independent from both craving and the type of the treatment. The rate of not attending the outpatient treatment unit at the end of the first month was 47.7% (30.2% for inpatients, 54.2% for outpatients). Previous studies conducted in different settings have reported that the rates of discontinuation of BN maintenance treatment within the first month following induction ranged between 37.2% and 50.0% 26, 28 . Thus the rate found in the present study is lower for inpatients but higher for outpatients than previous studies conducted in different countries and different settings. A common finding in the substance abuse treatment literature is that patients who stay in treatment longer have better outcomes 20, 24 . Retention rates for BN maintenance treatment at the 6 th month ranged from 35% to 59% in previous studies 12, 14, 24, 27 . Studies considering predictors of treatment outcome in opioid dependence have employed various measures, including treatment retention, rates of positive urine drug screenings, and continuous opioid abstinence. The main goal of treatment was retention in these previous studies. Although many patients report reductions in use in these studies, the only objective measure they had was urine toxicology testing; i.e. while Soeffing and Martin 26 reported that the overall retention rate was 56.9% for 1 year, they also stated that 64.7% of their months were opioid-negative. However, in the present study the main goal of treatment was continuous abstinence from both heroin and other illicit drugs, and retention in the treatment. This may be considered as "abstinent retention". Thus at the end of the 6th month, 26.8% were abstinent and were still in the BN maintenance treatment. This rate was higher among inpatients (38.7%) than outpatients (22.4%), and was even consistent with rates found in the previous studies that considered retention in the treatment as the main goal.
Severe psychiatric problems 30, 32 , poorer psychosocial functioning 29, 32 , and more severe legal problems 31 are some of the characteristics consistently associated with poorer outcome among heroin dependent patients in BN maintenance treatment. Consistent with these findings, having a first-degree relative with substance abuse, being under probation and a history of suicide attempts were higher in the RDG with a negative outcome. Being under probation and history of suicide attempts were also predictors of RDG, both with severity of craving and outpatient treatment, when treatment type was added in the analyses as an independent variable. BN maintenance treatment for opioid dependence consists of three phases: (a) induction, (b) stabilization, and (c) maintenance 16 . Of the three phases of BN treatment, induction, the initiation of BN treatment, is a key to treatment success. In fact, a substantial proportion of BN treatment failures occur during the first 7 days of treatment [57] [58] [59] . One reason for limited BN treatment is the challenge patients and providers face with BN induction 60, 61 . During this time, patients are typically expected to present to a healthcare setting in active opioid withdrawal, and physicians will manage the induction process by repeatedly assessing patients' signs and symptoms of withdrawal while titrating the BN dose. Results of the present study suggest that inpatients were retained in the treatment more at the end of the first month and following months. The first two weeks of the treatment, comprising induction and stabilization phases, seems to yield better results if conducted under supervision.
Receiving educational programs during this period may also have supported the abstinence of these inpatients. These factors may explain the finding of better outcomes for inpatients, who received a structured educational program and were given BN under supervision in the present study. Thus it is essential that new induction and stabilization strategies, based on existing models or theories in other countries, should be conducted with our outpatients when including them in BN maintenance treatment.
Both the induction and stabilization phases include the determination of the appropriate dose of BN to reduce and eliminate craving and signs and symptoms of withdrawal, which is essential to eliminate the use of other opioids and substances. One of the important findings of the present study was that, while craving and withdrawal were higher in the group with a negative outcome, the mean dose of BN for stabilization did not differ between the groups. The mean dose of BN in the first 2 weeks was not associated with outcome, similar to the findings in patients treated with comparable mean daily doses of 9-12 mg 35, 37, 62 . In one observational study, initial induction doses of 16 mg were associated with better retention 38 . In a metaanalysis, Mattick et al. 63 reported that higher doses of BN might suppress heroin use better than higher doses of methadone, although treatment retention may be poorer. The authors noted that slow BN induction in some studies might be associated with poorer retention. It is important to note that the doses of BN used in some of these clinical trials were lower than doses of BN currently recommended 64 . A review that evaluated primary treatment outcomes as a function of taper duration of BN suggested that taper duration was associated with opioid abstinence achieved during detoxification but not with other markers of treatment outcome 65 .
Unfortunately the results of the present study suggest better effectiveness of observed versus unobserved (inpatient versus outpatient) BN induction and stabilization. Hopefully, the development and validation of the unobserved BN induction method will lead to increased availability of effective opioid dependence treatment 66 .
Continuing education of clinicians beyond their initial training through conferences, articles, or formal mentoring is a strategy to reduce any perceived concerns and promote good practices 67 . Previous findings also support the need for clinicians to assess and address comorbid conditions, such as mood disorders and other substance use, which are prevalent among patients seeking treatment for heroin dependency 68, 69 . Other predictors of treatment outcome may also exist that were not examined in this trial, including genetic predictors, which have been found to be associated with pharmacotherapeutic treatment outcome in other populations of substance abusers 70, 71 . Different from the previous studies, the severity of craving, withdrawal, motivation, dependency and problems related with dependency were evaluated as pretreatment variables that may be related with outcome in the present study. It is hoped that knowledge about patient characteristics associated with successful (and unsuccessful) outcomes from the current study will be used to develop more effective treatments for this patient population. Since the dose of BN did not differ between the two groups, the present study suggests that those with high withdrawal symptoms or craving, particulary those with high frequency and severity of craving, may need a higher dose of BN. In addition, more observed (supervised) use of BN in the first two weeks may improve the outcome in outpatient maintenance treatment, particularly for those with a higher severity of problems related to dependency. At a minimum, the findings of the present study may suggest that clinics should review their dosing and monitoring methods. A re-assessment of treatment efficacy through a possible dosage increase or supportive psychosocial programs could potentially increase adherence to BN maintenance treatment 72, 73 .
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